Production of Brazilian human norovirus VLPs and comparison of purification methods by Lamounier, Thaís Alves da Costa et al.
BRAZILIAN JOURNAL OF MICROBIOLOGY 
 
 
 All the content of the journal, except where otherwise noted, is licensed under a 
Creative Commons License CC-BY. Fonte: 
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1517-





LAMOUNIER, Thais Alves da Costa et al. Production of Brazilian human norovirus VLPs and 
comparison of purification methods. Brazilian Journal of Microbiology, São Paulo, v. 46, n. 4, p. 
1265-1268, out./dez. 2015. Disponível em: 
<http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1517-
83822015000401265&lng=en&nrm=iso>. Acesso em: 2 abr. 2018. Epub Oct 09, 2015. doi: 
http://dx.doi.org/10.1590/S1517-838246420140925. 
Production of Brazilian human norovirus VLPs
and comparison of purification methods
Thais Alves da Costa Lamounier1, Layssa Miranda de Oliveira2,
Brenda Rabello de Camargo2, Kelly Barreto Rodrigues2, Eliane Ferreira Noronha2,
Bergmann Morais Ribeiro2, Tatsuya Nagata2
1Departamento de Farmácia, Universidade de Brasília, Brasília, DF, Brazil.
2Departamento de Biologia Celular, Universidade de Brasília, Brasília, DF, Brazil.
Submitted: November 5, 2014; Approved: April 12, 2015.
Abstract
Noroviruses (NVs) are responsible for most cases of human nonbacterial gastroenteritis worldwide.
Some parameters for the purification of NV virus-like particles (VLPs) such as ease of production
and yield were studied for future development of vaccines and diagnostic tools. In this study, VLPs
were produced by the expression of the VP1 and VP2 gene cassette of the Brazilian NV isolate, and
two purification methods were compared: cesium chloride (CsCl) gradient centrifugation and
ion-exchange chromatography (IEC). IEC produced more and purer VLPs of NV compared to CsCl
gradient centrifugation.
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Human noroviruses (HuNVs) are responsible for ma-
jor outbreaks of nonbacterial gastroenteritis for all ages
worldwide. HuNVs cause acute gastroenteritis in schools,
kindergartens, homes for the aged, cruise ships and even
hospitals. A million cases noroviral infection are verified
by laboratory diagnosis each year globally, and 110,000
and 19 million infections were observed last year in Ger-
many and the United States (CDC, 2014), respectively. A
large norovirus gastroenteritis outbreak occurred in the
Brazilian state of São Paulo in the summer of 2010 (Morillo
et al., 2011).
The HuNVs are classified into genogroups I (GI), II
(GII) and IV (GIV) of Norwalk virus species. GI currently
has nine genotypes, GII has 22 and GIV has two (La Rosa et
al., 2008; Kroneman et al., 2013). Among these genotypes,
GII.4 is responsible for most outbreaks detected in more
than 60-80% of cases of acute gastroenteritis caused by
NVs (Lindesmith et al., 2008). In Brazil, the surveillance of
acute diarrhea by the Ministry of Health still does not in-
clude this agent, so the impact of HuNV on public health in
Brazil is being studied for research groups in states such as
Rio Grande do Sul and Pará (Fioretti et al., 2011; de
Andrade et al., 2014; Siqueira et al., 2013).
Virus-like particles (VLPs) prepared by expressing
capsid genes using a baculoviral expression system is a use-
ful tool for studying uncultivable viruses such as HuNVs.
HuNV VLPs and the native particles have very similar
physicochemical and antigenic characteristics (Herbst-
Kralovetz et al., 2010; Fang et al., 2013). The VLPs have
thus been used for immunological studies producing poly-
and monoclonal antibodies against HuNV VLPs and also
for the search for the cellular receptors of NVs (Herbst-
Kralovetz et al., 2010; Tan et al., 2011). Immunological di-
agnostic tools such as ELISAs are very useful in public
health, but Brazil does not yet have a good and abundant
source of antibodies for NV diagnostics.
The self-assembling norovirus virus-like particles
with capsid protein expression has spurred the develop-
ment of vaccines, because the particles are assembled simi-
larly to the native viruses and do not cause infection. The
intranasal and oral administration of VLPs has been used
for inducing mucosal immunity against NV infection. Fur-
thermore, these particles are being used as tools to elucidate
the role of immune cells such as T and B lymphocytes in in-
fections caused by this virus. Studies of NV VLP vaccines
have focused on a single genogroup, but multivalent vac-
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cines using different genogroups are more interesting for a
broader protection (Sundararajan et al., 2015).
The objective of this study was to establish VLPs of
NV GII.4 by the expression of the VP1 and VP2 gene cas-
sette for future use as antigens for the development of diag-
nostic tools. The ease and efficiency of VLP purification
were also assessed by comparing ultracentrifugation using
cesium chloride and ion-exchange chromatography.
One fecal suspension positive for HuNV was ob-
tained from a seven-year-old child at the laboratory of Vi-
rology, Central Public Health Laboratory of the Federal
District (LACEN-DF), during a research project approved
by the Ethics Committee in Research for protocol Nº
SES/DF #93/09 on 11/05/2009. Total RNA was extracted
from this sample using Trizol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufactures in-
struction. Complementary DNA (cDNA) was obtained by
reverse transcription using Superscript III (Invitrogen) with
an oligo-dT primer (Oligo dT50M10: AAG CAG TGT
TAT CAA CGC AGA T50). The cDNA fragments of ap-
proximately 2.4 kb containing the complete VP1 and VP2
capsid genes and the 3’UTR (untranslated region) were am-
plified by PCR using NoroII-BamHI forward primer (TTT
GGA TCC ATG AAG ATG GCG TCG AAT GAC) and
PstI-SacI M10 reverse primer (TAT TCT GCA GAG CTC
AAG CAG TGT TAT CAA CGC AGA). The PCR was
performed using LongAmp Taq DNA polymerase (New
England Biolabs, NEB, Ipswich, MA, USA). The PCR
mixture was prepared as follows: 5 L of 5X LongAmp
Taq Reaction Buffer (NEB), 3 L of 2.5 mM dNTPs,
0.5 L each of forward and reverse primers (10 mM), 1 L
of cDNA, 1 L of LongAmp Taq DNA polymerase (2 U)
and Milli-Q water (Whatman-GE Healthcare Life Sci-
ences, Piscataway, NJ, USA) to 25 L. The cycle was set as
follows: pre-cycle denaturation step of 94 °C for 2 min, fol-
lowed by 35 cycles of denaturation at 94 °C for 30 s, an-
nealing at 56 °C for 30 s and extension at 65 °C for 3 min
and a final extension at 65 °C for 10 min.
The amplified cDNA containing the VP1 and VP2
genes and the 3’UTR was cloned in the pGEM-T Easy
plasmid (Promega, Madson, WI, USA) and subcloned in
the baculoviral system plasmid pFASTBac1 (Invitrogen,
Carlsbad, CA, USA). The cloning of this bicistronic gene
cassette by ribosomal termination-reinitiation was con-
firmed by sequencing by Macrogen Inc. (Seoul, Korea).
The expression of VP1 is sufficient for VLP assembly, but
the expression of the VP1-VP2-3’UTR gene cassette is a
better strategy for stable and efficient VLP formation
(Bertolotti-Ciarlet et al., 2003; Vongpunsawad et al.,
2013). After constructing the bacmid using the baculoviral
Bac-to-Bac system (Invitrogen) according to the manufac-
turer’s instructions, we produced the VP1 and VP2 proteins
in the insect cell lines BTI-4-Tn5B1, Sf9 and Sf21.
Preliminary testing indicated that VP1 expression
level was higher in the BTI-Tn5B1-4 than the Sf9 and Sf21
cells. VP1 is secreted into the culture medium in the baculo-
viral expression system, so VLP purification began with the
culture medium of the infected cells. The culture medium
(105 mL) was centrifuged at 5,000 x g at 4 °C for 10 min to
remove the cells, and the supernatant was ultracentrifuged
with 20% sucrose cushion at 115,878 x g for 1 h at 4 °C.
The pellet was resuspended in 0.5X PBS buffer (pH 5.5),
and the solution was added to the top of a cesium chloride
solution (CsCl 0.39 g/mL) diluted in 0.5X PBS pH 5.5, fol-
lowing the method by Ausar et al., 2006. The sample was
ultracentrifuged at 114,600 x g for 18 h at 4 °C. The upper,
middle and lower fractions were collected and dialyzed
three times in 0.5X PBS pH 5.5 with 3 h intervals. The sam-
ples were analyzed by SDS-PAGE and Western blotting
using a polyclonal antibody against NV (GII.4).
VLP assembly in the purified preparation was con-
firmed by transmission electron microscopy. A formvar-
coated nickel grid (200 mesh) was incubated over 40 L of
the purified VLP solution in PBS for 5 min, and the sample
grids were contrasted with 1% uranyl acetate for 5 min,
then air dried. The VLPs were observed with a JEM 1011
electron microscope (JEOL, Tokyo, Japan).
The VLPs were also purified by ion-exchange chro-
matography for comparison. After the 20% sucrose-
cushion ultracentrifugation, the pellet was resuspended
with sodium phosphate buffer (50 mM, pH 7.0). The VLPs
were purified under appropriate conditions by an ÄKTA
purifier (GE Life Sciences, Piscataway, NJ, USA) using a
HiTrap Q FF column (GE Life Sciences) at a flow rate of
150 cm/h (Koho et al., 2012). The bound protein was eluted
with stepwise increments in ionic strength to 1 M NaCl,
50 mM sodium phosphate buffer, pH 7.0. The NV VP1
fractions were collected with increasing salt concentrations
of 10, 20 and 40%. After purification by both methods
(CsCl isopycnic centrifugation and Ion-exchange chroma-
tography), the proteins were quantified by the NanoDrop
3300 Quant-iT Protein Assay (Invitrogen).
No bands were observed from CsCl ultracentrifuga-
tion, perhaps due to the low concetration of VLPs. The top,
middle and bottom fractions were again ultracentrifuged to
precipitate possible VLPs in each fraction. All three frac-
tions were subjected to SDS-PAGE and subsequent West-
ern blotting. The SDS-PAGE produced protein bands of
approximately 60 kDa, close to the expected size of 59 kDa
(Figure 1A). These proteins, however, were not the target
proteins. The Western blotting identified specific signals
only for the middle and bottom fractions of the CsCl ultra-
centrifugation (Figure 1B, lanes 4 and 5) but not for the
negative control and the top fraction (Figure 1B). Two spe-
cific signals of approximately 59 kDa and 56 kDa were
identified, which are the common sizes of VP1 produced by
the baculoviral expression system (Figure 1B arrow). The
smaller protein was the cleaved VP1 lacking the N terminus
(Ausar et al., 2006). We thus concluded that VP1 is an in-
soluble protein, which can be separated by ultracentrifuga-
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tion with a 20% sucrose cushion and with a buoyant density
heavy enough to remain in the middle and bottom fractions
of the CsCl gradient. The dispersed distribution of VLPs in
both fractions, however, suggested the failure of gradient
formation in the CsCl isopycnic centrifugation under the
conditions used.
The possibility of the presence of VP1 in the cultured
cells was also evaluated. The contents of the collected cells
were also subjected to SDS-PAGE and Western blotting af-
ter boiling for 5 min with Laemmli buffer containing SDS,
but almost no VP1 was detected from the infected cells
(data not shown).
To determine if the purified VP1 assembled VLPs,
we prepared grids with these two fractions. Round particles
with protruding structures, which are typical of the VLPs of
NV were observed by transmission electron microscopy
(Figure 2A). All VLPs had negatively stained central areas.
The diameter of the VLPs was estimated at approximately
40 nm, indicating T = 3 icosahedral particles. Natural virus
particles and adequate VLPs are T = 3 icosahedral capsids
containing 180 capsomeres of the VP1 protein, with a di-
ameter of approximately 40 nm (Tresset et al., 2013), but
artificial VLPs produced by VP1 expression also often
make T = 1 icosahedral particles of 23 nm. In our study, no
T = 1 particles were observed, indicating that the amino
acid sequence of the VP1 in this study showed the stable
characteristics of VP1 proteins for VLP assembly.
To determine relative VLP yields, we compared ion-
exchange chromatography to CsCl centrifugation. The col-
lected fractions were subjected to SDS-PAGE and Western
blotting (Figure 3). For visualizing the small amounts of
contaminant proteins, the SDS-PAGE gel was silver
stained, which is more sensitive than staining with
Coomassie Brilliant Blue (Figure 3A). Double protein
bands above the 50 kDa indicator protein were observed in
the SDS-PAGE (Figure 3A). The identities of these protein
bands as VP1 were confirmed by Western blotting (Figu-
re 3B).
The relative strengths of the signals in Figures 1B and
3B indicated that the yield of VP1 was higher by this
method than by CsCl ultracentrifugation. The formation of
VLPs was also confirmed by electron microscopy (Figu-
re 2B). Abundant VLPs were observed in this preparation
and the amount of VLPs obtained by ion-exchange chroma-
tography was greater than that obtained by CsCl centri-
fugation. The average yield of purified VLPs was
1.50 mg/L by CsCl centrifugation and 9.31 mg/L by ion-
exchange chromatography so the yield was 6.2-fold higher
for ion-exchange chromatography than for CsCl centri-
fugation. We also concluded that ion-exchange chromatog-
raphy produced purer VLPs than the CsCl gradient under
our conditions. NV VLP purification by ion-exchange
chromatography is recommended over CsCl centrifugation
and laboratory-scale VLP purification by CsCl ultracentri-
fugation often produces sufficient purity and yield, but the
procedure requires long ultracentrifugation times. Further-
more, this purification procedure may affect the morpho-
logical integrity, functionality and antigenicity of the
purified VLPs (Huhti et al., 2010). Ion-exchange chroma-
tography avoids these negative effects thus we concluded
that ion-exchange chromatography was the better of the
two methods in terms of quality and quantity of VLPs. In
addition, purification by ion-exchange chromatography
can be advantageous for large-scale VLP production for
vaccine development.
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Figure 1 - Analysis of fractions for VP1 proteins by SDS-PAGE and Western blotting prepared by CsCl isopycnic centrifugation. (A) SDS-PAGE gel
stained with Coomassie Brilliant Blue and (B) Western blotting using a polyclonal antibody against NV GII.4. Lane 1, PageRuler Prestained Protein Lad-
der (Thermo Scientific); lane 2, uninfected insect cells (negative control); lane 3, top fraction collected from CsCl centrifugation; lane 4, middle fraction;
lane 5, bottom fraction. The arrow in B indicates the specific reaction by Western blotting using the antibody against NV.
Figure 2 - Electron micrographs showing the virus-like particles (VLPs)
of NV with diameters of approximately 40 nm by negative staining. VLPs
prepared by A) CsCl isopycnic centrifugation and B) ion-exchange chro-
matography. Scale bar = 100 nm.
This study describes a convenient procedure for the
preparation and purification of NV VLP as a first step to-
ward NV surveillance in Brazil. Further development of
tools for studying NV is required to improve the epidemio-
logical study of NV in Brazil.
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Figure 3 - Analysis of fractions of VP1 proteins by SDS-PAGE and Western blotting prepared by ion-exchange chromatography. (A) Silver-stained
SDS-PAGE gel and (B) Western blotting using a polyclonal antibody against NV GII.4. Lane 1, unstained Novex Sharp Protein Standard ladder
(Invitrogen); lanes 2, 3 and 4, fraction 14 of the chromatogram after IEC; lanes 5, 6 and 7, fraction 15 after IEC; lane 8, uninfected insect cell lysate (nega-
tive control). Note: the proteins in the uninfected cell lysate identified by silver staining was not reactive in the Western blotting. The arrow in B indicates
the specific reaction by Western blotting using the antibody against NV.
